TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00134550
Drug: Atorvastatin (10 mg or 80 mg)
Normalized name: atorvastatin 80 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01256411
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optional add-on of amlodipine (5-10 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
Study: NCT01256411
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optional add-on of hydrochlorothiazide (HCTZ) (12.5-25 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
Study: NCT00122226
Drug: Lopinavir/ritonavir + zidovudine + lamivudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00122226
Drug: Lopinavir/ritonavir + nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01279499
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR \> 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes
Study: NCT01279499
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperatively sevoflurane will be guided by a target BIS of 40 - 50. If a positive sympathetic response occured (an elevation of the HR and/or MAP greater than 15% above baseline) a bolus SEVO 8 MAC will be administered for 2 minutes.
Study: NCT00232492
Drug: Ketamine 0,1 mg/kg males
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,1 mg/kg ketamine iv bolus males
Study: NCT00232492
Drug: Ketamine 0,3 mg/kg males
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,3 mg/kg ketamine iv bolus males
Study: NCT00232492
Drug: Ketamine 0,5 mg/kg males
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,5 mg/kg ketamine iv bolus males
Study: NCT00232492
Drug: Ketamine 0,1 mg/kg females
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,1 mg/kg iv bolus ketamine females
Study: NCT00232492
Drug: Ketamine 0,3 mg/kg females
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,3 mg/kg iv bolus ketamine females
Study: NCT00232492
Drug: Ketamine 0,5 mg/kg females
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,5 mg/kg iv bolus ketamine females
Study: NCT01292239
Drug: Peginterferon alfa-2a (pegIFN alfa-2a)
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PegIFN alfa-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks for patients randomized to TMC435 and for up to 48 weeks for patients randomized to placebo.
Study: NCT00459563
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200,000 IU once weekly for 3 weeks (600,000 IU total dose)
Study: NCT00459563
Drug: calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: calcitriol 0.5 mcg twice a day for 1 week
Study: NCT01130532
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administer orally
Study: NCT03870880
Drug: Risperidone ISM 75 mg
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly (once every 4 weeks) intramuscular (IM) injection in the gluteal or deltoid muscle.
Study: NCT03870880
Drug: Risperidone ISM 100 mg
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
Study: NCT01292239
Drug: Ribavirin (RBV)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is \> 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is \> 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
Study: NCT01398280
Drug: Topical aminocaproic acid (ACA) mixed with Vanicream
Normalized name: Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25% Aminocaproic acid cream twice daily for up to 12 weeks.
Study: NCT00762320
Drug: Low dose Kaletra tablets
DrugBank: Kale (DB14564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/Ritonavir tablets 100mg/25mg
Study: NCT03119324
Drug: Nimesulide Ratiopharm® and Flexiban®
DrugBank: Nimesulide (DB04743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five consecutive days assumption of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm® 50mg twice a day, followed by five consecutive days assumption of Myorelaxant, Flexiban®, 10mg once a day, followed by five consecutive days assumption of 50mg of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm®, twice a day
Study: NCT04559074
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry; starting dose equivalent to current dose for patients on amlodipine at entry or at next 1-2mg dose step (according to clinical need based on the Investigator's judgement). Investigation of whether gradually increasing the dose of liquid amlodipine (can be an add-on to existing amlodipine tablets) in small increments (e.g. 1-2mg) will enable blood pressure control within the sequence 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg to a maximum of 10mg amlodipine per day.
Study: NCT04491240
Drug: EXO 1 inhalation
Normalized name: exo-1,2-cis-Dimethyl-3,6-epoxyhexahydrophthalic anhydride
DrugBank: Cantharidin (DB12328)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the first type.
Study: NCT04491240
Drug: EXO 2 inhalation
Normalized name: exo-1,2-cis-Dimethyl-3,6-epoxyhexahydrophthalic anhydride
DrugBank: Cantharidin (DB12328)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the second type.
Study: NCT01263834
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
Study: NCT01263834
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
Study: NCT00939939
Drug: sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sitagliptin 100 mg/d for 10 weeks
Study: NCT00939939
Drug: glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: glimepiride 1 mg/d for 10 weeks
Study: NCT00960713
Drug: Rituximab (MABTHERA® or RITUXAN®).
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: patients can be included in the study whatever the dosage used. Most patients will receive a classical 375 mg/m2 dose every week during four times (J0-J7-J14-J21).
Study: NCT00061503
Drug: Travoprost
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00471003
Drug: Pritor (Telmisartan , BAY68-9291)
Normalized name: Pritox
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primary care hypertensive patients starting the therapy with Telmisartan
Study: NCT00387270
Drug: Dimebon
Normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimebon 10 or 20 mg TID x 7 days
Study: NCT00367432
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
Study: NCT02181985
Drug: Full dose TNK-tPA
Normalized name: TNK-tPA
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01846182
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: serotonin norepinephrine reuptake inhibitor
Study: NCT01846182
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: alpha-2-alpha subunit calcium channel ligand
Study: NCT02181985
Drug: Half dose TNK-tPA
Normalized name: TNK-tPA
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02181985
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00281281
Drug: vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00269035
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone tablets will be available with dose strength of 3 and 6 mg
Study: NCT01206998
Drug: Vaginal progesterone gel
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive daily vaginal progesterone gel provided by Columbia laboratories (1.125g progesterone gel containing 90mg (8%) progesterone)
Study: NCT02181985
Drug: Abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01125293
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01125293
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01125293
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00014911
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered at a dose of 0.2 mg/kg by mouth once pre-transplantation then 0.1 mg/kg daily post-transplantation. Dosing will be adjusted to achieve a trough peripheral blood level of 12-15 ng/mL x3 months after transplantation and 7-12 ng/mL for the remainder of the study.
Study: NCT00014911
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered at a dose of 1 mg by mouth once pre-transplantation followed by 1 mg twice daily post transplantation. Levels will be adjusted to achieve a peripheral blood trough level of 3-6 ng/mL for maintenance immunosuppression.
Study: NCT02275065
Drug: Bictegravir
Normalized name: Bictegravir
DrugBank: Bictegravir (DB11799)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bictegravir tablet(s) administered orally once daily
Study: NCT00377403
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention drug:~Dose: 500mg tid for 10 days
Study: NCT00377403
Drug: Dextromethorphan hydrobromide with guaifenesin
Normalized name: dextromethorphan hydrobromide / guaifenesin Pill
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Symptomatic treatment:~Dose: 10mls every 4 to 6 hours for cough
Study: NCT00377403
Drug: Guaifenesin
Normalized name: Guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Symptomatic treatment:~Dose: 600mg every 12 hours to thin secretions
Study: NCT00377403
Drug: Pseudoephedrine Sustained Action
Normalized name: pseudoephedrine
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Symptomatic treatment:~Dose: 120mg every 12 hours for nasal congestion
Study: NCT00377403
Drug: Saline spray (0.65%)
Normalized name: sodium chloride Nasal Spray [Simply Saline]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Symptomatic treatment:~Dose: 2 squeezes per nostril as needed for nasal congestion
Study: NCT03451734
Drug: metformin and lifestyle intervention
Normalized name: metformin and ertugliflozin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: different dose metformin combines lifestyle intervention
Study: NCT00360438
Drug: Rasburicase
Normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.15mg/kg intravenously over 30 minutes once per day for 5 consecutive days.
Study: NCT01276925
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7,5 mg/ml. 10 ml for the femoral nerve, 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
Study: NCT01276925
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7,5 mg/ml. 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
Study: NCT01276925
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotonic. 10 ml for the femoral nerve.
Study: NCT01276925
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg/ml. 3 ml for spinal anaesthesia.
Study: NCT00331643
Drug: ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03369379
Drug: D3 Vitamin
Normalized name: Vitamin D 400 IU/1 ML Oral Solution [D3 VITAMIN]
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a capsule of 50,000 units of vitamin D3 echa week for 12 weeks, basal levels of vitamin D will be taken and again at week 12.
Study: NCT01832948
Drug: Endostar
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01832948
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01832948
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01832948
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00504426
Drug: OPC-249
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)
Study: NCT03278262
Drug: Aflibercept (Eylea, BAY86-5321)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment-naïve eyes with neovascularization AMD (Age-related Macular Degeneration), with the indication to be treated with Aflibercept. One and/or two eyes per patient.
Study: NCT00134290
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00014911
Drug: Daclizumab
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered at a dose of 1 mg/kg intravenously immediately pre-transplantation and 2, 4, 6, and 8 weeks post-transplantation, totaling 5 doses(over 8 weeks). Further daclizumab dosing may be necessary based on individual results and islet transplantation needs.
Study: NCT00014911
Drug: Sulfamethoxazole
Normalized name: Sulfamethoxazole
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An antibacterial used to prevent opportunistic infections
Study: NCT00014911
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An antiviral used to kill viruses and stop viral replication
Study: NCT00014911
Drug: Trimethoprim
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An antibacterial used to prevent opportunistic infections
Study: NCT00014911
Drug: Pentamidine
Normalized name: Pentamidine
DrugBank: Pentamidine (DB00738)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An antiprotozoal used to prevent disease
Study: NCT00615797
Drug: standard interventions penicillin VK and haloperidol
Normalized name: penicillin V potassium Oral Tablet [Ledercillin VK]
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V K 500mg 12hrly po or 250mg 6 hrly for 10 days IM penicillin to be given at discharge, 1.2 million units if over 30 KG and 600,000 units if weight less than 30 KG haloperidol 0,025mg/kg/day orally in divided doses gradually increasing to a maximum of 0,05mg/kg/day
Study: NCT00719862
Drug: 0.15% azelastine hydrochloride Nasal Spray
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.15% azelastine hydrochloride 822 mcg
Study: NCT01576406
Drug: crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: crizotinib 250 mg twice a day
Study: NCT01576406
Drug: crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: crizotinib 250 mg once a day
Study: NCT02165345
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 162 mg tocilizumab will be administered by SC injection at the following intervals: pJIA participants less than (\<) 30 kilograms (kg): every 3 weeks; pJIA participants greater than or equal to (\>=) 30 kg: every 2 weeks; sJIA participants \<30 kg: every 2 weeks; sJIA participants \>/= 30 kg: once weekly
Study: NCT01278134
Drug: danoprevir
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg bid orally, up to 24 weeks
Study: NCT01278134
Drug: peginterferon alfa-2a [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 mcg sc weekly, 24 weeks
Study: NCT01278134
Drug: ribavirin [Copegus]
DrugBank: Ribavirin elaidate (DB17193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
Study: NCT01278134
Drug: ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg bid orally, up to 24 weeks
Study: NCT00969501
Drug: EUFLEXXA
Normalized name: Euflexxa
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mL of EUFLEXXA (per injection) x 3 injections
Study: NCT00003038
Drug: suramin
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00331747
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01511510
Drug: PF-04958242
Normalized name: PF-04958242
DrugBank: PF-04958242 (DB11843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04958242 0.05 mg oral solution Q24 hours for 14 days
Study: NCT00406003
Drug: Paroxetine controlled release tablet
Normalized name: paroxetine Extended Release Oral Tablet
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paroxetine will be given as single dose, controlled release tablet with dosing strengths of 12.5, 25 and 37.5 milligrams in fasted state separated by a wash-out period of 10 days.
Study: NCT01511510
Drug: PF-04958242
Normalized name: PF-04958242
DrugBank: PF-04958242 (DB11843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04958242 0.10 mg oral solution Q24 hours for 14 days
Study: NCT01511510
Drug: PF-04958242
Normalized name: PF-04958242
DrugBank: PF-04958242 (DB11843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04958242 0.15 mg oral solution Q24 hours for 14 days
Study: NCT01530230
Drug: oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous bolus dose given during 1 minute after clamping of the umbilical cord
Study: NCT02657031
Drug: Prochlorperazine
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prochlorperazine 10 mg IV
Study: NCT02657031
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine 0.3 mg/kg IV
Study: NCT02657031
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydromine 25 mg IV
Study: NCT02657031
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron 4 mg IV
Study: NCT03542305
Drug: Lorlatinib
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lorlatinib single oral dose
Study: NCT00826826
Drug: Amiodarone
Normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: From the day of the catheter ablation procedure and 8 weeks forward.
Study: NCT01511510
Drug: PF-04958242
Normalized name: PF-04958242
DrugBank: PF-04958242 (DB11843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04958242 0.25 mg oral solution Q24 hours for 14 days
Study: NCT01938612
Drug: tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tremelimumab is administered by IV infusion every 4 weeks
Study: NCT01457911
Drug: Glimepiride and Metformin hydrochloride combination (HOE490)
Normalized name: glimepiride and pioglitazone
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT01457911
Drug: Glimepiride (HOE490)
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral